Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse Vybrance system.
Mountain biker Jerry Veggian overcame atrial fibrillation with pulse field ablation. AFib cases expected to grow from 5 million to 12 million Americans.
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...
Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc.
Growing up in El Paso, Joe Udell used to spend much of his free time racing bikes. From the age of 14, he rode nearly every weekend in El Paso and neighboring Ciudad Juárez. This weekend passion would ...
Pulse Biosciences, led by billionaire Robert Duggan, focuses on nonthermal nsPFA technology for soft tissue ablation, particularly in cardiology and benign thyroid nodule treatments. Despite promising ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results